OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 326,700 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Jennifer Pritzker sold 326,700 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $23.04, for a total value of $7,527,168.00. Following the sale, the insider owned 6,536,764 shares in the company, valued at $150,607,042.56. The trade was a 4.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

OrthoPediatrics Stock Performance

KIDS opened at $23.00 on Wednesday. The company has a market cap of $600.53 million, a P/E ratio of -13.69 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The firm’s 50-day moving average price is $21.61 and its 200-day moving average price is $18.76. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its stake in OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the period. Legal & General Group Plc purchased a new position in OrthoPediatrics in the 2nd quarter valued at about $34,000. Northwestern Mutual Wealth Management Co. boosted its holdings in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter worth about $54,000. Finally, BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after buying an additional 1,235 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

Wall Street Analyst Weigh In

KIDS has been the subject of a number of recent research reports. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Needham & Company LLC lifted their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 target price on OrthoPediatrics in a research note on Wednesday, August 5th. Finally, Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.